Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-Controlled Study
American Journal of Respiratory and Critical Care Medicine, 08/19/2011
Castro M et al. – The most common adverse events with reslizumab were nasopharyngitis, fatigue, and pharyngolaryngeal pain. Interpretation: Patients receiving reslizumab showed significantly greater reductions in sputum eosinophils, improvements in airway function, and a trend toward greater asthma control than those receiving placebo. Reslizumab was generally well tolerated.